NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis $0.92 +0.03 (+3.61%) As of 02:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biofrontera Stock (NASDAQ:BFRI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biofrontera alerts:Sign Up Key Stats Today's Range$0.87▼$0.9350-Day Range$0.78▼$1.1552-Week Range$0.55▼$1.19Volume121,880 shsAverage Volume360,320 shsMarket Capitalization$11.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue. The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis. Ameluz is used in combination with the BF-RhodoLED® lamp, a medical device designed to emit the precise wavelength of red light required to activate the gel. This integrated pharmaceutical–device approach underpins the company’s position in the PDT market. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera maintains operations in multiple geographies, including a U.S. subsidiary established to support commercialization efforts in North America. Beyond its approved indications, the company is exploring additional dermatological uses for its photodynamic platform and is engaged in discussions with regulatory authorities and commercial partners to expand its presence in key markets such as Canada, Turkey and beyond. Biofrontera’s management team brings together expertise in dermatology, pharmaceutical development and medical device manufacturing. The company continues to invest in its pipeline, seeking to leverage its PDT technology for new indications and to forge strategic partnerships that will broaden access to its therapies worldwide.AI Generated. May Contain Errors. Read More Biofrontera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreBFRI MarketRank™: Biofrontera scored higher than 18% of companies evaluated by MarketBeat, and ranked 787th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingBiofrontera has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiofrontera has only been the subject of 1 research reports in the past 90 days.Read more about Biofrontera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($0.30) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biofrontera's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 10.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment1.36 News SentimentBiofrontera has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biofrontera this week, compared to 2 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Biofrontera is held by insiders.Percentage Held by Institutions10.08% of the stock of Biofrontera is held by institutions.Read more about Biofrontera's insider trading history. Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BFRI Stock News HeadlinesBiofrontera Conference Highlights AMELUZ Growth, 80% Margins and FDA CatalystsMay 30 at 4:33 AM | americanbankingnews.comBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026May 21, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.June 1 at 1:00 AM | Brownstone Research (Ad)Benchmark downgrades Biofrontera (BFRI)May 20, 2026 | msn.comBiofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...May 14, 2026 | finance.yahoo.comBiofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business UpdateMay 14, 2026 | globenewswire.comBiofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic KeratosisMay 13, 2026 | globenewswire.comBiofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026May 8, 2026 | markets.businessinsider.comSee More Headlines BFRI Stock Analysis - Frequently Asked Questions How have BFRI shares performed this year? Biofrontera's stock was trading at $0.57 on January 1st, 2026. Since then, BFRI stock has increased by 62.6% and is now trading at $0.9270. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.30. The company had revenue of $10.08 million for the quarter, compared to the consensus estimate of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative trailing twelve-month return on equity of 515.34%. Read the conference call transcript. When did Biofrontera's stock split? Biofrontera shares reverse split before market open on Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Biofrontera IPO? Biofrontera (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META). Company Calendar Last Earnings5/14/2026Today6/01/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (17m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 BFRI's financial health is in the Yellow zone, according to TradeSmith. BFRI has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BFRI CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees70Year Founded2012Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.54 million Net Margins-25.66% Pretax Margin-25.60% Return on Equity-515.34% Return on Assets-53.91% Debt Debt-to-Equity Ratio0.78 Current Ratio1.20 Quick Ratio1.09 Sales & Book Value Annual Sales$41.71 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book1.02Miscellaneous Outstanding Shares12,800,000Free Float12,188,000Market Cap$11.75 million OptionableNo Data Beta0.83 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:BFRI) was last updated on 6/1/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BFRI Stock Alerts